Suchergebnisse - "Cicin, Irfan"

PubPharm (222)

1

Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer : analyses from the monarchE study

enthalten in: NPJ breast cancer | 2024

von Goetz, M. | Cicin, I. | Testa, L. | +12

2

RESILIENT Part 2 : A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Spigel, D. | Dowlati, A. | Chen, Y. | +115

3

Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC

enthalten in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners | 2024

von Karadurmuş, N. | Ökten, �. | Türk, H. | +25

4

Genetic testing and counseling challenges in personalized breast cancer care : review article with insights from Türkiye

enthalten in: Future oncology (London, England) | 2024

von Cicin, I. | Karadurmus, N. | Bilici, A. | +9

5

Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer : Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Rastogi, P. | O'Shaughnessy, J. | Martin, M. | +20

ErratumIn: J Clin Oncol. 2024 Apr 30;:JCO2400711. - PMID 38687953

6

Adrenocortical Cancer in the Real World : A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG)

enthalten in: Clinical genitourinary cancer | 2024

von Yasar, H. | Aktas, B. | Ucar, G. | +30

7

Is the "P-value" Alone a Sufficient Metric for the Magnitude of Clinical Benefit and Which Clinical Trial Is Actually Positive, KEYNOTE-394 or KEYNOTE-240?

enthalten in: The oncologist | 2024

von Kus, T. | Aktas, G. | Cicin, I.

8

A perspective : the integration of ctDNA into Response Evaluation Criteria in Solid Tumours 1.1 for phase II immunotherapy clinical trials

enthalten in: Immunotherapy | 2024

von Kus, T. | Cicin, I.

9

The prognostic factors in patients with advanced hepatocellular carcinoma : impact of treatment sequencing

enthalten in: Journal of chemotherapy (Florence, Italy) | 2024

von Köstek, O. | Demirel, A. | Hacıoğlu, M. | +44

10

Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC : A Randomized, Open-Label, Phase 3 Trial

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2023

von Cho, B. | Lee, J. | Wu, Y. | +22

CommentIn: J Thorac Oncol. 2023 Dec;18(12):1629-1631. - PMID 37993216

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[23]